APOTEX INC. Plaintiff v. H. LUNDBECK A/S, 2013 FC 192
Opinion
Date: 20130312 Docket: T-1407-09 Citation: 2013 FC 192 BETWEEN: APOTEX INC. Plaintiff and H. LUNDBECK A/S Defendant AND BETWEEN: H. LUNDBECK A/S Plaintiff by Counterclaim and APOTEX INC. and APOTEX PHARMACHEM INC. Defendants by Counterclaim PUBLIC REASONS FOR JUDGMENT (Confidential Reasons for Judgment Issued 26 February 2013) HARRINGTON J. [ 1 ] This action for impeachment of a patent of invention and the counterclaim for its infringement deal with the compound known as Escitalopram or (+)-Citalopram.
It belongs to a class of compounds known as SSRIs (Selective Serotonin Reuptake Inhibitors, or 5-HT reuptake inhibitors). It has proved useful in the treatment of clinical depression. It is branded in Canada as Cipralex, in the United States as Lexapro and in the United Kingdom as Cipramil. It was invented in Denmark in 1988, and has been patented in Canada, and in many other countries. The patent claims (+)-Citalopram itself, as well as methods to make it and non-toxic salts thereof. [ 2 ] Apotex Inc. has wanted to market its generic version of (+)-Citalopram for some time.
It was first thwarted by Lundbeck who obtained a Court order pursuant to the Patented Medicines (Notice of Compliance) Regulations [PM (NOC) Regulations] the effect of which was to prohibit the Minister of Health from issuing a Notice of Compliance. That Notice would have permitted Apotex market entry. However, the order did not purport to determine whether or not the patent was valid. [ 3 ] In this action Apotex seeks a declaration that Canadian patent 1,339,452 (‘452) is, and has always been, invalid.
Lundbeck, for its part, has counterclaimed that Apotex and a related corporation, Apotex Pharmachem Inc., have infringed the patent. It seeks,
among other things, an accounting of profits. Apotex admits that if the patent is valid, in whole or in part, it has infringed. Apotex Pharmachem Inc. produced (+)-Citalopram through a method not covered by the patent. Thus, it has infringed only if Lundbeck’s claim for the compound (+)-Citalopram itself is valid. [ 4 ] An invention must be something new. Apotex alleges that (+)-Citalopram is not new so that Lundbeck invented nothing at all.
It says (+)-Citalopram was anticipated in the prior literature and, as well, was obvious to those to whom the patent is addressed. [ 5 ] In order to be patentable, an invention must also be useful. In a later patent application, Lundbeck stated that the Pamoic Addition Salt of (+)-Citalopram was toxic.
Since that salt figures in the claims for (+)-Citalopram itself the patent is alleged to be invalid for inutility. [ 6 ] The subject matter must also be patentable ( Harvard College v Canada (Commissioner of Patents) , 2002 SCC 76 , [2002] 4 SCR 45, [2002] SCJ No 77 (QL); Monsanto Canada Inc v Schmeiser , 2004 SCC 34 , [2004] 1 SCR 902, [2004] SCJ No 29 (QL)). However, this is not in issue in the present case. [ 7 ] A patent represents a bargain between the inventor and the state.
In consideration of the grant of a monopoly, the inventor must fully and properly disclose the invention so that when the monopoly expires, others may reproduce the product or process involved without undue difficulty. The Patent Act requires the applicant to provide a specification which discloses what has been invented and how to replicate it. The specification ends with a claim or series of claims over which a monopoly is asserted.
According to Apotex, the specification is fatally defective. [ 8 ] One of the claims of the patent, claim number 7, which on its face is a method or process for preparing (+)-Citalopram, is said to be insufficiently disclosed and is not based on routine techniques which would have been known to the skilled addressee in 1988. The other process claims are also invalid because they are dependent on claim number 7. [ 9 ] The patent is also allegedly insufficient because it states that “[r]esults upon administration to human beings have been very gratifying”.
There had actually been no tests on human beings at the time of the application. This constitutes a failure to fully disclose the invention. [ 10 ] There need not be proof positive to back up statements, or promises, in a specification. The statement may be premised on a prediction, as long as there is a sound basis therefor. As shall be seen, (+)-Citalopram is an enantiomer of the racemate Citalopram, which together with precursors thereof was covered by earlier patents. By 1988, Citalopram had proved useful in the treatment of depression.
According to Apotex, the ‘452 patent promises that (+)-Citalopram is therapeutically more potent than Citalopram. There was no sound basis for making that prediction as (+)-Citalopram had not as then been tested in human beings. The fact that the prediction later turned out to be true is irrelevant. [ 11 ] I shall deal with both invalidity and infringement. As I stated at trial, no matter my holding on validity, I would deal with infringement.
If I were to hold that the patent is invalid, and be reversed in appeal, the likelihood is that the matter would be referred back to me to deal with the counterclaim for infringement. Hence, it is better to cover all aspects of the litigation now. [ 12 ] These reasons are broken down as follows: PARAGRAPHS I. PATENT CONSTRUCTION 13-19 II. THE SKILLED ADDRESSEE 20-23 III. AN ORGANIC CHEMISTRY PRIMER 24-33
IV. THE EXPERTS 34-52 V. PATENT ‘452 53-59 VI. HISTORY OF THE PROCEEDINGS 60-68 VII. INVALIDITY A. Anticipation B. Obviousness i. Motivation ii. Resolution iii. Chiral HPLC iv. The Experiments v. Lundbeck’s Efforts vi. Mosaic of Prior Art C. Inutility D. Insufficient Disclosure E. Sound Prediction 69-254 69-78 79-218 99-119 120-161 162-195 196-202 203-207 208-218 219-224 225-240 241-254 VIII. INFRINGEMENT A. Punitive Damages B. Accounting of Profits C. The Profits D. Delivery-Up or Destruction E. Permanent Injunction F. Interest 255-311 257-266 267-272 273-304 305 306 307-311 IX. COSTS 312 X.
CONFIDENTIALITY 313-314 XI. DRAFTING OF JUDGMENT 315 PARAGRAPHS I. PATENT CONSTRUCTION [ 13 ] The starting point of any inquiry into either invalidity or infringement is the language and meaning of the patent within the context of the Patent Act ( Free World Trust v Électro Santé Inc , 2000 SCC 66 , [2000] 2 SCR 1024, 9 CPR (4th) 168, [2000] SCJ No 67 (QL); Whirlpool Corp v Camco Inc , 2000 SCC 67 , [2000] 2 SCR 1067, 9 CPR (4th) 129, [2000] SCJ No 68 (QL)). [ 14 ] Patents are a creature of statute, in this case the Patent Act , as it was immediately prior to 1 October 1989.
[ 15 ]
Section 34 thereof required that the patent application contain a specification cumulating with a claim or claims “defining distinctly and in explicit terms the subject-matter of the invention for which an exclusive privilege or property is claimed.” It must be sufficiently full, clear, concise and exact “as to enable any person skilled in the art or science to which it pertains, or to which it is most closely connected, to make, construct, compound or use it.” [ 16 ] The claims are to be read in an informed and purposive way so as to permit fairness and predictability and to define the limits of the monopoly.
One way of doing this is to separate the essential from the non-essential. As Mr. Justice Binnie stated in Whirlpool at paragraph 45: The key to purposive construction is therefore the identification by the Court, with the assistance of the skilled reader, of the particular words or phrases in the claim that describe what the inventor considered to be the “essential” elements of his invention. [ 17 ] However, ultimately, it is not for the skilled reader to tell the Court what the patent means; it is for the Court to tell the parties what it means. A patent is not an ordinary document.
It meets the definition of a “regulation” in the
Interpretation Act , and must be read to assure the attainment of its objects. “[C]laims construction is a matter of law for the judge, and he was quite entitled to adopt a construction of the claims that differed from that put forward by the parties.” ( Whirlpool at para 61.) [ 18 ] Pursuant to
section 27 of the Patent Act , as it was, an inventor or legal representative thereof was entitled to obtain a patent for: …an invention that was (
a) not known or used by any other person before he invented it, (
b) not described in any patent or in any publication printed in Canada or in any other country more than two years before presentation of the petition hereunder mentioned, and (
c) not in public use or on sale in Canada for more than two years prior to his application in Canada …une invention qui
a) n'était pas connue ou utilisée par une autre personne avant que lui-même l'ait faite,
b) n'était pas décrite dans quelque brevet ou dans quelque publication imprimée au Canada ou dans tout autre pays plus de deux ans avant la présentation de la pétition ci-après mentionnée, et
c) n'était pas en usage public ou en vente au Canada plus de deux ans avant le dépôt de sa demande au Canada [ 19 ] An invention was defined at
section 2 as meaning: […] any new and useful art, process, machine, manufacture or composition of matter, or any new and useful improvement in any art, process, machine, manufacture or composition of matter […] Toute réalisation, tout procédé, toute machine, fabrication ou composition de matières, ainsi que tout perfectionnement de l'un d'eux, présentant le caractère de la nouveauté et de l'utilité. II. THE SKILLED ADDRESSEE [ 20 ] According to the abstract in the patent specification, the invention relates to the two novel enantiomers of Citalopram and to their use as antidepressant compounds as well as to possible use as geriatrics or in the cure of obesity and alcoholism.
[ 21 ] Citalopram is stated to be 1-(3-Dimethylaminopropyl)-1,-(4’-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, and is accompanied by a diagram of the chemical formula. [ 22 ] It goes without saying that the patent is not addressed to this Court as presently constituted. The Court needs the assistance of experts in order to understand its technical aspects. The patent is notionally addressed to a person skilled in the art or science to which the subject matter relates and is to be read as such a person would have read it when it first became public, which was in June 1988.
The parties have called a great array of experts to assist the Court in this regard. There is no significant disagreement as to the identity of this hypothetical skilled addressee. He or she is a medicinal chemist, probably with a doctorate, and has spent at least a few years in a laboratory. The addressee is either part of or has access to a team, which includes analytical chemists, familiar with the principles of organic chemistry and techniques then available which could be used in an effort to separate racemic mixtures into their two enantiomers.
Access would also be had to pharmacologists, psychiatrists and to drug formulators. [ 23 ] More shall be said about this skilled addressee under the topic of Obviousness. III. AN ORGANIC CHEMISTRY PRIMER [ 24 ] This case deals with the element “carbon”, which is essential to human life. Indeed carbon is the very subject of organic chemistry. There is no disagreement among the experts as to the basic principles involved. [ 25 ] Drawing upon the opinion of Dr.
Martin Semmelhack, a professor of chemistry at Princeton University, called by Apotex, organic chemistry concerns the study of molecules containing carbon atoms. Molecules are collections of atoms arranged in a particular order. Carbon atoms can form bonds both with other carbon atoms and with other atoms. These bonds may take the form of long chains or cyclic structures. They are three-dimensional. [ 26 ] Atoms bond to each other in various ways.
Covalent bonds arise from atoms sharing electrons, while ionic bonds (common in salts) are bonds between charged atoms. [ 27 ] Turning now to stereochemistry, isomers are molecules which have the same molecular formula but either have different connectivities among the atoms (known as constitutional isomers), or have the same connectivity but different orientation in space (known as stereoisomers). [ 28 ] Stereoisomers are molecules with the same atoms and the same chemical bonds but different in how they are oriented in space. Two varieties are enantiomers and diastereomers.
Enantiomers are non-superimposable mirror images of one another. The word chiral, Greek for handedness, is often used because the two human hands are non-superimposable mirror images of each other.
Diastereomers are stereoisomers that are not enantiomers. [ 29 ] Enantiomers share all the same physical and chemical characteristic such as boiling point, melting point and solubility. [ 30 ] Because enzymes and protein receptors in the body are chiral, they may react differently with one or the other enantiomer of the same compound. [ 31 ] When natural substances are recreated in a laboratory, the result is often a 50/50 mixture of the two enantiomers. This mixture is known as a racemate.
The two enantiomers within may be identified by whether they rotate a plane of polarized light to the right, identified as the (+) enantiomer, or to the left, identified as the (-) enantiomer. Another method of identifying them is based on the sizing of atoms attached to the carbon centre, in accordance with what are known as the Cahn-Ingold-Prelog rules. In a molecule with a single stereogenic centre, one will be known as the S-enantiomer and the other as the R-enantiomer. There is no direct correlation between the (+) and (-) and the R and the S nomenclatures.
Citalopram is S- and (+). [ 32 ] Because enantiomers have the same physical and chemical characteristics, it may be difficult, if not impossible, to separate them. However, unlike enantiomers, diastereomers have different chemical and physical properties, such as different solubility and melting points. This difference plays an important role in techniques which can be used to resolve a racemate in order to isolate enantiomers. This is one of the fundamental challenges of this case.
[ 33 ] All agree it was common general knowledge in 1988 that racemates could be easily identified by their chemical structure, and that there might well be differences between the two enantiomers, and between each of the enantiomers and the racemate. In terms of medicine, it was also common general knowledge that since one enantiomer might react better than the other with enzymes and protein receptors within the body, one might have more therapeutic effect than the other. The other might even have most unfortunate side effects.
However, knowledge of the characteristics of the enantiomers could only be had by resolving the racemate in sufficient quantity to allow for testing. IV. THE EXPERTS [ 34 ] As part of its impeachment case, Apotex called Dr. Martin F. Semmelhack, Dr. Rick Lane Dannheiser, Dr. Peter Jenner, Mr. Thomas Beesley, Dr. John Caldwell and Dr. René Levy. Apotex’s factual witnesses were also experts in their own right. Unless ordered otherwise, a party is limited to five experts. However, on consent, I ordered that both parties could call more than five expert witnesses. [ 35 ] For its part, Lundbeck called Dr.
Stephen Graham Davies, Dr. Daniel Wayne Armstrong, Dr. Peter Myers, Dr. Pierre Blier and Dr. Gerd Bode. Lundbeck’s factual witnesses were also experts in their own right. [ 36 ] Then in reply to the evidence of Dr. Davies, Apotex called Sir Jack Baldwin and recalled Dr. Dannheiser. [ 37 ] Each side called one expert witness with respect to the calculation of profits in the event of infringement. Dr. Martin Semmelhack [ 38 ] Dr. Semmelhack is currently the Associate Chair of the Chemistry Department at Princeton University.
The focus of his early independent research in the late 1960s at Cornell University was organic synthesis. He is an organic chemist well aware of stereochemistry, racemates and enantiomers. Since the 1970s, he has taught concepts, including the resolution of racemic mixtures and the impact of stereochemistry on biological systems. He is well respected in academia and is a noted author. His career has been spent in academia, except in 1988 and 1989 when he served as Department Head of Medical Chemistry and then as Consulting Director at the Medical Research Division of American Cyanamid.
He was qualified as an expert in organic chemistry and organic synthesis. His evidence focused on ways and means Citalopram, or a precursor thereof, could be resolved into its two enantiomers, based on the common general knowledge, literature and techniques readily available to the addressee of the ‘452 patent in 1988. Dr. Rick Lane Dannheiser [ 39 ] Dr. Dannheiser obtained his Ph.D in Organic Chemistry from Harvard University in 1978, the same year in which he joined the Massachusetts Institute of Technology. He is their Arthur C. Cope Professor of Chemistry.
His laboratory currently deals with the development of new strategies for the synthesis of complex molecules. He too is well published, and was qualified as an expert in organic chemistry and synthetic organic chemistry. Like Dr. Semmelhack, his opinion related to ways and means to arrive at (+)- Citalopram, without recourse to the ‘452 patent. Mr. Thomas Beesley [ 40 ] Mr. Beesley has a master of science degree from St. John’s University. His career has been in industry.
He was at the forefront of the development of some of the analytical tools for separating racemates, including High Performance Liquid Chromatography (HPLC), which was cutting-edge technology in the 1980s. In 1983, he came across Dr. Armstrong, called by Lundbeck. Dr. Armstrong was on the lecture circuit promoting molecules known as Cyclodextrins which could facilitate the resolution of various isomers. To that end, he and Dr. Armstrong formed Advanced Separation Technologies Inc (Astec) .
He was qualified as an expert in chromatography, one of the techniques available to resolve racemates, and, in particular, by the use of chiral HPLC. Dr. Peter Jenner [ 41 ] Dr. Jenner is emeritus professor of pharmacology at King’s College, London. He began his training as a pharmacist. His doctorate at the University of London was in the area of drug metabolism and pharmacokinetics. He has worked throughout his career with medical chemists, clinical neurologists and psychiatrists.
He was qualified as an expert in pharmacology, drug metabolism and pharmacokinetics, particularly with respect to centrally active drugs used to treat psychiatric and neurological disorders. His testimony did not relate to ways and means to resolve racemates but rather as to reasons to resolve them. In other words, he dealt with what would have motivated the skilled addressee at the time to arrive at (+)-Citalopram.
Dr. John Caldwell [ 42 ] Dr. Caldwell served as Dean of the Faculty of Medicine of the University of Liverpool from 2002 to 2010 and Pro-Vice Chancellor of that University from 2007 until his retirement last year. He is currently professor emeritus . He has a Ph.D in Biochemistry from St Mary’s Hospital Medical School and in 1987 received his doctorate of science in Pharmacology from the University of London for distinction in drug metabolism. The focus of his work has been upon, among other things, the importance of stereochemistry in drug development.
He is an author and editor and serves or has served on the editorial boards of a number of scientific publications. In 1989, he co-founded the journal Chirality to address a diverse range of issues relating to stereochemistry, including drug development, pharmacology, synthesis and analysis. He has consulted both with government regulators and industry. Consequently, he qualified to give expert advice as a pharmacologist with expertise in drug metabolism and pharmacokinetics and as to the significance of stereochemistry in drug development, including regulatory policy and practice referable thereto.
He testified as to the importance of stereochemistry to pharmaceutical companies and government regulators in the 1980s. Dr. René Levy [ 43 ] Dr. Levy is professor emeritus at the Department of Pharmaceutics at the University of Washington, and advisor to the Metabolism and Transport Drug Interaction Database which he founded in 2002. He obtained his Ph.D in Pharmaceutical Chemistry from the University of California in 1970.
In 1977, he became a full professor of pharmaceutical sciences and adjunct professor of neurological surgery at the University of Washington, and served as Chairman of the Department of Pharmaceutics in its School of Pharmacy from its inception in 1980 until 2006. He has specialized in drug metabolism and like the other experts, is a noted author. He was qualified as an expert in metabolism, pharmacokinetics and pharmacodynamics of drug products and their metabolites, including the consequences of stereoselectivity therein.
He dealt with statements, or implications, in the patent about the use of (+)-Citalopram as an antidepressant in humans, whether it was predicted that it had more therapeutic benefits than Citalopram itself, and whether there was a sound basis for making such a prediction. Dr. Stephen Graham Davies [ 44 ] For its part, Lundbeck called Dr. Davies. He has been teaching at the University of Oxford since 1980, where he is the Waynflete Professor of Chemistry. From 2006 to 2011, he was also chairman of its Department of Chemistry.
He obtained his Ph.D in Chemistry from Oxford in 1975 and his doctorate of science degree in Chemistry from the University of Paris in 1980. In 1989, he founded and is still editor-in-chief of Tetrahedron Asymmetry , a journal which reports advances in knowledge of stereochemistry. In 1991, he founded and is the Director of Oxford Asymmetry International PLC. He has received various awards and has acted as a consultant to a number of pharmaceutical companies.
He has given evidence in affidavit form or viva voce on behalf of Lundbeck in a number of jurisdictions in which the (+)-Citalopram invention has been challenged. [ 45 ] There was some debate as to whether he should have been qualified, as proposed by Lundbeck, in medicinal chemistry. In the end, I qualified him as an expert in medicinal chemistry and organic chemistry, including resolution techniques, and stereochemistry. His testimony covered a broad range of topics, including obviousness and insufficiency. He also commented on the expert reports of Drs. Semmelhack, Dannheiser, Caldwell and Jenner. Dr.
Daniel Armstrong [ 46 ] Dr. Armstrong is the Robert A. Welch Professor of Chemistry at the University of Texas at Arlington. He teaches courses in separation science and directs research at the undergraduate and graduate levels in bio-analytical chemistry, separation science, colloid science and organic chemistry. He has expertise in separation of racemic mixtures by various methods, including fractional recrystallization, kinetic resolutions, direct crystallization of enantiomers and chiral HPLC.
He is a named inventor on 14 United States patents, mainly related to the separation of racemic mixtures by HPLC and other separation techniques. As aforesaid, together with Mr. Beesley, he helped found Astec, a company specializing in enantiomeric separations, mainly using Cyclodextrin chiral HPLC columns. He was frequently retained by scientists and clients to attempt to separate enantiomers, and has regularly consulted with both brand name and generic pharmaceutical companies on issues related to the separation of enantiomers.
Again, as with the other experts, his credentials, his expertise, his publications and his role on editorial boards are most impressive. He was qualified as an expert in resolution techniques, including chiral HPLC. Dr. Peter Myers [ 47 ] Dr. Myers is a professor of separation science in the Department of Chemistry at the University of Liverpool. His career has been split between industry and academia. He has been very much involved in the study and synthesis of silica microparticles for HPLC.
Beginning in 1979, he worked with Phase Separations, a United Kingdom company involved in the manufacture and distribution of chromatography products. After its purchase by Waters Corporation, an American company, in 1995, he continued as a consultant. He has been involved in the development of silica products, including products used by Astec, the company established by Dr. Amstrong
and Mr. Beesley. He was qualified as an expert in separation science, including chromatography and the manufacture of chromatographic silica. He testified as to the feasibility of arriving at (+)-Citalopram in 1988 by means of chromatography. Dr. Pierre Blier [ 48 ] Dr.
Blier is currently a full professor at the Department of Psychiatry in cellular and molecular medicine, Faculty of Medicine, University of Ottawa; adjunct professor, Department of Psychiatry, McGill University; adjunct professor, Department of Neuroscience, Carleton University; and Director of the Mood Disorders Research Program at the University of Ottawa’s Institute of Mental Heath Research. He obtained his Ph.D in Neuroscience from the Université de Montréal in 1985. He has obtained many peer reviewed research grants and has written extensively.
He was qualified as an expert in neuropsychology including pharmacokinetics and pharmacodynamics with respect to SSRIs. He is also a physician specializing in the treatment of mental health illnesses, more particularly depression. He testified with respect to the therapeutic benefits of (+)-Citalopram and the promises, if any, in the patent, with respect to its benefits in the treatment of depression in humans in comparison with Citalopram. Dr. Gerd Bode [ 49 ] Dr. Bode’s expert report was taken as read. He was not cross-examined by Apotex.
He has an M.D. and Ph.D and is an expert in pathology, neuropathology, pharmacology and toxicology. His evidence related to the alleged toxicity of (+)-Citalopram Pamoate. Sir Jack Baldwin [ 50 ] Apotex called Sir Jack Baldwin to reply to the opinion of Dr. Davies with respect to the “Baldwin Rules”, so called, which he had developed in the 1970s. He was Dr. Davies’ predecessor as the Waynflete Professor of Chemistry at Oxford, and has been the recipient of many awards. A knighthood was conferred upon him in 1997 for his contributions in organic chemistry.
He was qualified as an expert in organic, synthetic and biological chemistry. Like Dr. Davies, he has given evidence in other jurisdictions with respect to (+)- Citalopram, however always on the side that submitted the patent should be held to be invalid. [ 51 ] Finally, Dr. Dannheiser was re-called to take issue with some of Professor Davies’ opinions. [ 52 ] I say, without hesitation, that not only were all these witnesses superbly qualified to offer expert opinion to the Court, but they were, each and every one, over qualified.
They are not ordinary medicinal chemists, ordinary analytical chemists, ordinary pharmacologists and what have you. Each and every one is a superstar. The challenge they faced, and the challenge facing the Court, is whether they were able, in a sense, to reduce their expertise to that of the skilled addressee in 1988. V. PATENT ‘452 [ 53 ] The application was filed 13 June 1989. The patent was issued 9 September 1997, good for 17 years. Its priority date is stated to be 14 June 1988, the date of the first patent application which was filed in the United Kingdom.
Lundbeck has suggested an April priority date, on the grounds that that was when (+)-Citalopram was invented. However, it did not pursue that point with vigour and, in any event, the experts agree that the situation did not change between April and June 1988. [ 54 ] Its inventors were two Lundbeck employees: Dr. Klaus Peter Bøgesø and Jens Perregaard. [ 55 ] To expand upon the abstract, according to Dr. Jenner, the patent is addressed to chemists and pharmacologists with knowledge of antidepressant drugs. It relates to the enantiomers of Citalopram and their use in the treatment of depression in humans.
It also relates to methods for obtaining those enantiomers. [ 56 ] Claims 1 through 5 relate to (+)-Citalopram itself, including in salt form and composition, while claims 6 through 11 relate to an intermediate compound and methods of using that compound to make (+)-Citalopram. These comments are not controversial. What is more controversial is the view of some that there is a prediction that (+)-Citalopram is more potent in humans than Citalopram. [ 57 ] Dr.
Davies notes that the specification states that it had now (in 1988) proved possible to resolve the intermediate diol of Citalopram into its enantiomers and in a stereoselective way to convert those enantiomers to the corresponding Citalopram enantiomers. A “diol” is an alcohol containing two hydroxyl groups in its molecule.
[58] The patent then sets out two methods of resolution, called “A” and “B”-“C”, described in chemical reaction schemes. Thesereactions involve resolution of the intermediate diol or an ester thereof followed by conversion of the resultant precursor molecules intothe enantiomers of Citalopram by the use of specific reagents and conditions. I shall expand upon this later on in these reasons. [59] The specification ends with 11 claims: i. Claim 1 is for Citalopram and non-toxic acid addition salts thereof. ii. Claim 2 covers the Pamoic Acid Salt of (+)-Citalopram. iii.
Claim 3 covers an antidepressant pharmaceutical composition containing an effective amount of (+)-Citalopram,accompanied by a pharmaceutically acceptable diluent or adjuvant. iv. Claim 4 is identical to claim 3, except that the composition is of the Pamoic Acid Salt of (+)-Citalopram as the activeingredient. v. Claim 5 is dependent on claims 3 and 4, and is a pharmaceutical composition in unit dosage form. vi. Claim 6 is directed to the (-) enantiomer of the intermediate diol, and an ester thereof. vii. Claim 7 refers to a method of producing (+)-Citalopram. viii.
Claims 8 through 11 are methods dependent on claim 7. VI. HISTORY OF THE PROCEEDINGS [60] It all began with the PM (NOC) Regulations.
They have been the subject of numerous decisions, including those of theSupreme Court in Merck Frosst Canada Inc v Canada (Minister of National Health and Welfare), (SCC), [1998] 2SCR 193, 80 CPR (3d) 368, [1998] SCJ No 58 (QL); Bristol-Myers Squibb Co v Canada (Attorney General), 2005 SCC 26, [2005] 1SCR 533, [2005] SCJ No 26 (QL), at paragraphs 5-24; and Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61, [2008] 3 SCR265, [2008] SCJ No 63 (QL) (Plavix), at paragraphs 7 and 12-17. [61] In accordance with those Regulations, in April 2007 Apotex served a Notice of Allegation upon Lundbeck Canada Inc., thelicensee of the patent.
The notice asserted that patent ‘452 was invalid on various grounds. One of those grounds, an invalid selectionpatent, was not pursued in this trial.
In turn, Lundbeck filed a Notice of Application in this Court, court docket number T-991-07 thefollowing month, in which it sought an order in accordance with the Regulations that the Minister of Health be prohibited from issuing aNotice of Compliance until the expiration of the patent. [62] In February 2009, in Lundbeck Canada Inc v Canada (Minister of Health), 2009 FC 146, 343 FTR 53, [2009] FCJ No 249(QL), I upheld the application and so prohibited the Minister from issuing Apotex a Notice of Compliance.
This decision was affirmedby the Federal Court of Appeal, 2010 FCA 320, 88 CPR (4th) 325, [2010] FCJ No 1504 (QL). Application for leave to appeal to theSupreme Court was dismissed, SCC Case Information 34066. [63] The PM (NOC) Regulations are, in theory,
summary in nature. They were not thought binding upon the parties either as tovalidity or infringement. The issue was simply whether the Minister should have been prohibited from, in effect, licensing Apotex. Theparties are entitled to litigate validity and infringement in an action, as opposed to an application. Lundbeck only had to meet theallegations set out in the Notice of Allegation, which did not even raise the issue of non-infringement. [64] As I mentioned in those proceedings, a trial is much more to be desired from the judge’s point of view, and indeed from theparties’ point of view.
Unlike in an action, in an application there is no full discovery of documents and examination for discovery. Thereis no live testimony in court. The evidence is limited to affidavits and cross-examinations thereon. The Court is unable to ask clarifyingquestions of the expert witnesses. In this trial most of the experts are new and much of the evidence is different. [65] It is not all that uncommon that a patent be held invalid at trial, even though the Minister had earlier been prohibited fromissuing a Notice of Compliance. In Plavix, above, the Supreme Court upheld this Court’s issuance of a prohibition order.
However, at thesubsequent trial on the merits, the patent was held to be invalid (Apotex Inc v Sanofi-Aventis, 2011 FC 1486, 101 CPR (4th) 1, [2011]FCJ No 1813 (QL), currently in appeal).
[ 66 ] This Court has developed the practice, where possible and practicable, to assign the trial to the judge who heard the Notice of Compliance application. The theory is that these pharmaceutical patents have a long learning curve, and so it is better to assign the trial to a judge who has already looked at the patent. This, without more, does not give rise to a conflict of interest, or to an apprehension of bias ( Sanofi-Aventis Canada Inc v Apotex Inc , 2008 FCA 394 , [2008] FCJ No 1692 (QL)). [ 67 ] I raised this point fairly early on at a trial management conference.
The parties were agreeable that I be the trial judge. Indeed, they, Apotex in particular, shaped their evidence to deal with a concern I had had, which was that the experts benefited from hindsight and were not looking at (+)-Citalopram with 1988 eyes. [ 68 ] I shall now deal with the allegations of invalidity. VII. INVALIDITY A. Anticipation [ 69 ] The leading Canadian case is the decision of the Supreme Court in Plavix , above.
Section 27 of the Patent Act as it was at the relevant time required, among other things, that the patent be “not described in any patent or in any publication printed in Canada or in any other country more than two years before presentation of the petition hereunder mentioned…” [ 70 ] According to Apotex, the claims for (+)-Citalopram itself as a compound, namely claims 1 through 5, are invalid as they were anticipated by the prior disclosure of (+)-Citalopram as a component of Citalopram. [ 71 ] There were previous patents, issued more than two years before the application, which disclosed Citalopram, for instance US Patent 4,136,193.
It was common general knowledge that Citalopram was a racemate, containing equal amounts of (+)-Citalopram and (- )-Citalopram. It was also common general knowledge that the enantiomers might have different therapeutic effects one from the other, and from the racemate itself. [ 72 ] However, the working of patent ‘193 or of the intermediate diol disclosed in US Patent 4,650,884 would inevitably result in a racemic mixture, not in separate enantiomers. This is fatal to Apotex’s submission. [ 73 ] The test for anticipation was set out by Mr.
Justice Hugessen speaking for the Federal Court of Appeal in Beloit Canada Ltd v Valmet Oy (1986), 8 CPR (3d) 289, [1986] FCJ No 87 (QL) , as follows, at page 297: One must, in effect, be able to look at a prior, single publication and find in it all the information which, for practical purposes, is needed to produce the claimed invention without the exercise of any inventive skill.
The prior publication must contain so clear a direction that a skilled person reading and following it would in every case and without possibility of error be led to the claimed invention. [ 74 ] This test was approved by the Supreme Court in Free World Trust , above. [ 75 ] In Plavix , Mr. Justice Rothstein, after referring to recent English authority, held that there are two aspects to anticipation: prior disclosure and enablement. Prior disclosure means that working the prior patent would necessarily result in infringement thereof. [ 76 ] He held that the Beloit decision only dealt with prior disclosure. Mr.
Justice Hugessen had no need to consider whether the working of the invention was also enabled by that disclosure. [ 77 ] In this case, there was no prior disclosure in that the prior patents did not teach how to resolve Citalopram and did not disclose the therapeutic effects of (+)-Citalopram. [ 78 ] Apart from the patents, D.F.
Smith of the Psychopharmacology Research Unit, Psychiatric Hospital, Risskov, Denmark, had published two articles: “Stereochemical Considerations of the Actions of Some Psychotropic Drugs” in 1985 in Pharmacopsychiat and “The Stereoselectivity of Serotonin Uptake in Brain Tissue and Blood Platelets: the Topography of the Serotonin Uptake Area” in 1986
in Neuroscience & Biobehavorial Reviews. However, these papers do not explain in any way how to obtain the enantiomers ofCitalopram. Furthermore, he predicted that the activity would be concentrated in the R enantiomer while it turns out most of the activityis in the S enantiomer. B. Obviousness [79] Unlike
section 28.3 of the Patent Act currently in force, the Act at the time did not specifically provide that the subject matterof a claim must not be obvious “to a person skilled in the art or science to which it pertains…” However, it has always been accepted thatsection 28.3 is merely declaratory in that by its very definition, an invention must be new (Plavix, above, at para 51). [80] Who then is this skilled addressee? In Whirlpool Corp v Camco Inc, 2000 SCC 67, [2000] 2 SCR 1067, 9 CPR (4th) 129,[2000] SCJ No 68 (QL), above, at paragraph 42, Mr.
Justice Binnie quoted Consolboard Inc v MacMillan Bloedel (Saskatchewan) Ltd, (SCC), [1981] 1 SCR 504, at page 517, to say that the patent must describe the invention “with sufficiently completeand accurate details as will enable a workman, skilled in the art to which the invention relates, to construct or use that invention when theperiod of the monopoly has expired.” [81] If the “invention” is obvious to such a person, it is not patentable. [82] The skilled addressee in patent law does not exist. He or she is a judicial creation. When applied to the concept ofobviousness, Mr.
Justice Hugessen stated in Beloit Canada Ltd v Valmet Oy, above, as quoted by Mr. Justice Rothstein in Plavix (ApotexInc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61, [2008] 3 SCR 265, [2008] SCJ No 63 (QL)) at para 52: The test for obviousness is not to ask what competent inventors did or would have done to solve the problem. Inventors are by definitioninventive. The classical touchstone for obviousness is the technician skilled in the art but having no scintilla of inventiveness orimagination; a paragon of deduction and dexterity, wholly devoid of intuition; a triumph of the left hemisphere over the right.
Thequestion to be asked is whether this mythical creature (the man in the Clapham omnibus of patent law) would, in the light of the state ofthe art and of common general knowledge as at the claimed date of invention, have come directly and without difficulty to the solutiontaught by the patent. It is a very difficult test to satisfy. [83] Another useful commentary is found in the decision of Mr. Justice Laddie in Lilly Icos LLC v Pfizer Ltd, [2000] EWHCPatents 49 at para 62: The question of obviousness has to be assessed through the eyes of the skilled but non-inventive man in the art.
This is not a real person.He is a legal creation. He is supposed to offer an objective test of whether a particular development can be protected by a patent. He isdeemed to have looked at and read publicly available documents and to know of public uses in the prior art. He understands alllanguages and dialects. He never misses the obvious nor stumbles on the inventive. He has no private idiosyncratic preferences ordislikes. He never thinks laterally. He differs from all real people in one or more of these characteristics.
A real worker in the field maynever look at a piece of prior art – for example he may never look at the contents of a particular public library or he may be put offbecause it is in a language he does not know. But the notional addressee is taken to have done so. This is a reflection of part of the policyunderlying the law of obviousness. Anything which is obvious over what is available to the public cannot subsequently be the subject ofvalid patent protection even if, in practice, few would have bothered looking through the prior art or would have found the particularitems relied on.
Patents are not granted for the discovery and wider dissemination of public material and what is obvious over it, but onlyfor making new inventions. A worker who finds, is given or stumbles upon any piece of public prior art must realise that the art andanything obvious over it cannot be monopolised by him and he is reassured that it cannot be monopolised by anyone else. [84] Of course, it is important not to take these words “au pied de la lettre” (Hollier v Rambler Motors (AmC) Ltd, [1972] 1 All ER399 at 409, [1972] 2 QB at 80 and Gillespie Brothers & Co Ltd v Roy Bowles Transport Ltd [1973] 1 All ER 193 (CA)).
The passagesare not construing a statute. For example, in Plavix, above, Mr. Justice Rothstein limited Mr. Justice Hugessen’s famous statement withrespect to anticipation to prior disclosure and not to enablement. [85] There are a number of issues to consider, such as: i. Was (+)-Citalopram obvious to those to whom the patent is addressed? ii. Was it “obvious to try” the techniques successfully used by Lundbeck? iii. Was there a motivating factor, or reason to arrive at (+)-Citalopram?
iv. Was it “obvious to try” other techniques? v. Was it plain and obvious that the techniques used or which could have been used would have been successful? vi. Would the results of experiments successfully carried out in 2012 have been the same if carried out in 1988? Were such experiments a matter of routine? vii. Did the inventors have an easy time of it? [ 86 ] In order to decide whether (+)-Citalpram was obvious, whether it was obvious to apply various techniques and whether it was likely that those techniques would work, it is necessary to understand what Lundbeck actually did.
To summarize the evidence of Dr. Semmelhack, the patent described three synthesis processes. [ 87 ] The first process involves: i. the conversion of the Citalopram diol to a covalent diastereomeric ester through the addition of an optically pure acid chloride and hydride or labile ester in an inert organic solvent; ii. the purification of the diastereometers by either chromatography (in particular, HPLC) or crystallization; and iii. the addition of a strong base to effect a ring closure and yield a single enantiomer of Citalopram.
There is a strong difference of expert opinion with respect this ring closure, which was necessary for chirality. [ 88 ] The second process resolves the Citalopram diol into its two enantiomers through the addition of an optically active acid, some examples of which were given. [ 89 ] The third process involves the conversion of the pure enantiomers prepared according to the second process.
The synthesis consists of: i. the conversion of the primary alcohol to labile ester; and ii. the simultaneous addition of a base in an inert organic solvent at 0 degrees Celsius. [ 90 ] Apotex submits that what was done was well within the common general knowledge of the skilled addressee and the state of the art in 1988. Certainly, resolution was the most obvious technique. This involved resolution of diastereomers, both covalent and ionic. [ 91 ] The other technique would be based on chiral HPLC.
Notwithstanding that Lundbeck had tried HPLC without success, success should have been expected no matter the method in no more than a week. [ 92 ] There is a difference of opinion whether one would start with Citalopram itself, or with a precursor.
I find that if one did not work, the person skilled in the art would then try the other. [ 93 ] As I see it, the issue is not so much which techniques the skilled addressee might have used in an effort to arrive at (+)- Citalopram, but rather whether those techniques would have been successful, given the wide range of chemicals and other variables which might be used in the reactions. This boils down to whether or not it was “obvious to try” certain techniques and whether at one point one might give up in frustration. The burden of proof lies with Apotex.
The Plavix decision, above, which also dealt with a racemate and enantiomers is most instructive. In speaking for the Court, Mr. Justice Rothstein said at paragraph 66: For a finding that an invention was “obvious to try”, there must be evidence to convince a judge on a balance of probabilities that it was more or less self-evident to try to obtain the invention.
Mere possibility that something might turn up is not enough. [ 94 ] He approved the four-step approach developed by Oliver L.J. in Windsurfing International Inc v Tabur Marine (Great Britain) Ltd , [1985] R.P.C. (59) (C.A.), later updated by Jacob L.J. in Pozzoli SPA v BDMO SA , [2007] F.S.R. 37 (p. 872), [2007] EWCA Civ 588, at para 23:
In the result I would restate the Windsurfing questions thus: (1) (
a) Identify the notional “person skilled in the art”; (
b) Identify the relevant common general knowledge of that person;
(2) Identify the inventive concept of the claim in question or if that cannot readily be done, construe it;
(3) Identify what, if any, differences exist between the matter cited as forming part of the “state of the art” and the inventive concept of the claim or the claim as construed;
(4) Viewed without any knowledge of the alleged invention as claimed, do those differences constitute steps which would have been obvious to the person skilled in the art or do they require any degree of invention? [ 95 ] Mr. Justice Rothstein was of the view that it was in the fourth step of the Windsurfing/Pozzoli approach that the “obvious to try” issue will arise. [ 96 ] If that approach is warranted, he went on to say at paragraph 69: If an “obvious to try” test is warranted, the following factors should be taken into consideration at the fourth step of the obviousness inquiry.
As with anticipation, this list is not exhaustive. The factors will apply in accordance with the evidence in each case. 1. Is it more or less self-evident that what is being tried ought to work? Are there a finite number of identified predictable solutions known to persons skilled in the art? 2. What is the extent, nature and amount of effort required to achieve the invention? Are routine trials carried out or is the experimentation prolonged and arduous, such that the trials would not be considered routine? 3.
Is there a motive provided in the prior art to find the solution the patent addresses? [ 97 ] At trial, a great deal of evidence was led as to ways and means available in 1988 to separate the enantiomers of Citalopram in sufficient quantity that their characteristics could be tested; whether these techniques would have come to the mind of the skilled addressee and whether he or she would have been bothered to try them. Experiments had been carried out in an effort to show that it either would have been easy to resolve Citalopram, or difficult, depending on who commissioned the experiment. [ 98 ] Dr.
Timothy Ward, who successfully resolved Citalopram in the months before trial, using one of Dr. Armstrong’s inventions, said that his experiment was much like following a recipe in a cookbook. If there were not so much case law on point, I would have tended to think that the person who could arrive at the desired result, without benefit of the patent in question, i.e. without the cookbook, had a higher skill set than the patent addressee. It is one thing to follow a recipe, quite another to make it. i. Motivation [ 99 ] Motivation took on a life of its own.
Apotex said there was great motivation at the time to resolve pharmaceutical racemates as regulatory authorities, particularly in the two largest markets, the United States and Japan, were interested. For its part, Lundbeck downplayed motivation. I am troubled by the concept of motivation. Wishing does not make something come true. Wishing does not make something easier. A motive is defined as that which moves or tends to move a person to a particular course of action ( Oxford Dictionary ). On the other hand, there may not have been reason to do something at a particular point in time.
For instance, there may have been little interest in increasing automobile fuel efficiency in the 1950s. Lack of interest would not give rise to a patent if what was eventually done was obvious.
[ 100 ] I find that Lundbeck was motivated to resolve Citalopram. It was common general knowledge that each of the three dimensional enantiomers might fit into their receptors in the human body in a different way so that one might be more beneficial than the other. The other, as mentioned above, might have undesirable, or even tragic, side effects. [ 101 ] Thalidomide was mentioned in that one enantiomer was very beneficial in treating morning sickness in pregnant women while the other caused terrible birth defects.
However, the thinking now seems to be that the body converted the good enantiomer back into the racemic mixture, i.e. fifty percent of the “good” enantiomer was converted by the body into the “bad” enantiomer. [ 102 ] The United States Federal Drug Administration (FDA) was developing an interest and, indeed, asked Lundbeck’s American licensee to provide information with respect to the enantiomers of Citalopram if, as and when they became available. However, it was not, and it is still not, a regulatory requirement that racemates be broken down before they receive FDA approval.
That regulatory regime, which requires clinical testing on humans, is quite distinct from the patent regime, although it must be said a patent for a medicine is not particularly useful if the medicine cannot be marketed. It was not necessary to demonstrate the efficacy of (+)- Citalopram through clinical trials on humans if the patent disclosed a rational basis for making a sound prediction that it would prove useful ( Apotex Inc v Wellcome Foundation Ltd , 2002 SCC 77 , [2002] 4 SCR 153, [2002] SCJ No 78 (QL) at para 3 (AZT)). [ 103 ] Apart from the professional pride of one of the inventors who testified, Dr.
Bøgesø, academics were becoming interested in Citalopram. Lundbeck was concerned that someone else might resolve it first, which would have blocked it from patenting (+)- Citalopram and lead to a diminution of profits in that, at best, there would be cross-licensing agreements. [ 104 ] While motivation would make it obvious to try to resolve Citalopram, as Mr.
Justice Rothstein said at paragraph 65 of Plavix , above, “I am of the opinion that the “obvious to try” test will work only where it is very plain or, to use the words of Jacob L.J., more or less self-evident that what is being tested ought to work.” The reference to Lord Justice Jacob is to Saint-Gobain PAM SA v. Fusion Provida Ltd ., [2005] EWCA Civ 177 (BAILII) at para 35: Mere possible inclusion of something within a research programme on the basis you will find out more and something might turn up is not enough. If it were otherwise there would be few inventions that were patentable.
The only research which would be worthwhile (because of the prospect of protection) would be into areas totally devoid of prospect. The “obvious to try” test really only works where it is more-or-less self-evident that what is being tested ought to work. [ 105 ] In Plavix , Mr. Justice Rothstein also referred to the decision of Mr. Justice Kennedy, speaking for a unanimous United States Supreme Court in KSR International Co. v. Teleflex Inc. , 127 S. Ct. 1727 (2007). He quoted Mr.
Justice Kennedy at para 58, as follows: At p. 1742, he was clear that “obvious to try” could be a relevant test in an obviousness inquiry: The same constricted analysis led the Court of Appeals to conclude, in error, that a patent claim cannot be proved obvious merely by showing that the combination of elements was “obvious to try.” . . . When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp.
If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under §103. [ 106 ] The facts of KSR were very different from those in Plavix and in the case at bar. It dealt with electronic sensors in automobile gas pedals. It was held that mounting a modular sensor on a fixed pivot point of the pedal was a design step well within the grasp of a person of ordinary skill in the relevant art.
The patent in issue had been based on a combination of elements found in the prior art. As Mr.
Justice Kennedy stated at page 1739: For over a half century, the Court has held that a patent for a combination which only unites old elements with no change in their respective functions . . . obviously withdraws what is already known into the field of its monopoly and diminishes the resources available to skillful men. […] The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results. [ 107 ] He continued at pages 1741 and 1742: In determining whether the subject matter of a patent claim is obvious, neither the particular motivation nor the avowed purpose of the patentee controls.
What matters is the objective reach of the claim. If the claim extends to what is obvious, it is invalid […] One of the
ways in which a patent’s subject matter can be proved obvious is by noting that there existed at the time of invention a known problem for which there was an obvious solution encompassed by the patent’s claims. [ 108 ] On balance, I find that motivation was a neutral factor. As noted by Mr. Justice Kennedy, the patentee’s motivation does not control. There is a balance to achieve. If motivation inspires one to try harder or to think of a wider range of approaches, at some point the experiments are no longer routine. Some inventiveness is involved. [ 109 ] This case turns on expert opinion.
How can the Court decide which opinion is to be preferred? Certainly not on the experts’ knowledge of chemistry; not even on their knowledge of chemistry as it was in 1988. Even then, these overqualified experts had far greater skill sets than the ordinary person skilled in the art. [ 110 ] One way, advanced by Apotex, was to seize upon the fourth question in Windsurfing/Pozzoli , as cited by Justice Rothstein in Plavix “viewed without any knowledge of the alleged invention as claimed.” Drs.
Semmelhack and Dannheiser were simply given the formula for Citalopram and asked how the hypothetical chemist of ordinary skill would obtain a single enantiomer thereof. On the other hand, Dr. Davies was well familiar with the ‘452 patent, and foreign variations thereof, as he had testified on behalf of Lundbeck in several previous cases. This factor can hardly be determinative, because, if so, one could only testify once as an expert. At some point, the expert must look at the patent. [ 111 ] If you do not like the message, shoot the messenger. While Apotex could not challenge Dr.
Davies’ knowledge of chemistry, it urged me to pay little heed to his opinion because he was part of Lundbeck’s litigation team. [ 112 ] Lundbeck could hardly have been taken aback by this approach because it did the very same thing in the PM (NOC) proceedings. It urged then that the opinion of an expert witness, who was not called in this trial, should be discounted because he had been called upon by Apotex to testify more than 30 times. If he was a man for all patents, then Dr. Davies is said to be a man for one patent, over and over again and again.
I refused to downplay an opinion on that basis then and I refuse now. [ 113 ] For example, it was pointed out that Dr. Davies attended the opening statements. Experts are entitled to be present throughout trial. [ 114 ] His written opinion in this case, and his testimony, were not on all fours with other cases. However, it should be kept in mind that at times Lundbeck has been the defendant or respondent, and at other times the plaintiff or the applicant. For instance, in the PM (NOC) proceedings, the issues were circumscribed by Apotex’s Notice of Application. There was no need for Dr.
Davies to deal with what had not been alleged. [ 115 ] He has always said that there were at least 13 ways in which to separate racemates. It was suggested that he was attempting to make the problem more difficult than it was. The issue, however, is whether or not there were 13 different ways. He was never contradicted. Furthermore, it is clear, at least to me, from reading his report, and from his testimony, that most of these techniques would be immediately discarded by him and by the skilled addressee who looked at the chemical formula of Citalopram or one of its precursors.
The statement simply provided context. [ 116 ] As regards diastereomer separation, the technique successfully used by Lundbeck, he stated in his report “It should be noted that the differences between the two diastereomers produced may well be (and often are) so small that the diastereomers cannot be separated using this method, in particular by crystallization.” He did not say that in other reports. However, the issue is not what he said or did not say elsewhere; the issue is whether or not in general that statement is true. He was never contradicted, and so I take it as true. Neither Dr. Semmelhack nor Dr.
Dannheiser was particularly fond of crystallization. [ 117 ] He was a somewhat cautious, hesitant witness, which is not surprising considering the vigour of the cross-examination. While he was not as spontaneous as, say, Dr. Dannheiser, I am not going to pick and choose among the experts based on their personalities.
The advice I received was what the experts thought was within the grasp of the skilled addressee at the time, the common general knowledge and the literature searches which could, and should, have been carried out. [ 118 ] For its part, Lundbeck’s submission as to why I should prefer the opinion of Dr. Davies over that of Drs Semmelhack and Dannheiser is that even in 1988 they were pre-eminent experts in the field, and that their knowledge and insight were far and away
superior to that of the skilled addressee. There is something to that. [ 119 ] I turn now to the different techniques which the experts thought the skilled addressee would have contemplated. ii. Resolution [ 120 ] Although the experts cited a number of methods by which (+)-Citalopram could be achieved, it all comes down to two methods: chemical resolution and chiral HPLC. [ 121 ] As to chemical resolution, the principal experts were Drs. Semmelhack, Dannheiser and Davies. Sir Jack Baldwin was brought in to deal with the Baldwin Rules and Dr.
Armstrong, who dealt with chiral HPLC, was called upon to comment on resolution techniques in his cross-examination. [ 122 ] The issue is not so much how to go about it theoretically, but rather whether certain techniques would have been obvious to the “ordinary” medicinal chemist and his or her team in 1988, and whether they would have worked. Drs. Semmelhack and Dannheiser each came up with a resolution method without even having the patent at hand, a method very similar to the patent.
Apotex says that since they could do it, having put themselves in the shoes of the “ordinary” medicinal chemist, it was therefore obvious to those to whom the patent was addressed. Lundbeck submits that this simply proves their point that the two doctors were so overskilled they could not put themselves in the shoes of the “ordinary” medicinal chemist in 1988. I agree with Lundbeck. [ 123 ] Dr.
Semmelhack considered a skilled chemist would expect to obtain a single enantiomer in four ways: i. form diastereomeric salts of Citalopram which could then be separated by fractional crystallization; ii. form a covalent diastereomer of a diol precursor which could then be separated by fractional crystallization or chromatography; iii. form a diastereomeric salt of a diol precursor of Citalopram of the compound which could then be separated by fractional crystallization; and iv. chiral chromatography.
However he was not an expert in that area and could not comment. [ 124 ] The skilled chemist would work from the diol described in US Patent 4650884, issued in 1987, but based on a UK priority date of 1984. [ 125 ] Citalopram itself is set out in US Patent 4136193, granted in 1979, based on a UK priority date of 1976. [ 126 ] He explained that the difference between the state of the art and the innovative concept was that the state of the art “contains no explicit recital of the preparation (+)-Citalopram by resolving the (-)-Citalopram-diol and performing a ring closure that avoids racemization at the key stereogenic center”.
However he thought the skilled chemist would not have needed to exercise any inventive ingenuity because the chemical methodologies set out in the ‘452 patent were based on fundamental principles of organic synthesis and were well-known. [ 127 ] He opined that Dr. Bøgesø, one of the inventors, unlike the theoretical addressee, had biases against the diol route. He overlooked the fact that ring closure could be effected in basic conditions.
The diol route would be preferred because it would enable chromatographic resolution which would be virtually certain to work. [ 128 ] At the time, the skilled chemist would have used mainstream techniques to purify, or separate, a given substance. Both f ractional crystallization and chromatography exploit differences in the physical and chemical properties of the different components of a given mixture.
[ 129 ] The skilled chemist would use fractional crystallization to exploit the difference between solubilities of components of a mixture and how they crystallize. He or she would form a salt of the compound in question. If it is an acid, a base is added. If it is a base, an acid is added. The acid-base reaction is carried out in a solution which would then be cooled with the hope the substances would crystallize. The crystallized substance or precipitate generally contains more of the less soluble substance, as the more soluble would prefer to remain in the solution.
This technique can be repeated time and time again, and has been used for a number of years. That being so, he warned, however, that crystals do not always readily form, and it is not certain that the components of the mixture will have sufficiently different solubilities to allow for purification.
However, no such uncertainty is present in the case of chromatography. [ 130 ] Chromatography (not chiral HPLC) involves : i. the packing of a tube or column with an absorbent powder which is called the stationary phase; ii. applying the molecule to be purified to that phase; iii. pouring the mobile phase or solvent through the column; and iv. collecting the material that passes through.
Different material will be eluted at different times because the different components of the mixture form attractions of different strengths with the stationary phase. [ 131 ] As to the literature search, he personally had no need but the skilled addressee could refer to some standard textbooks and some specific to stereochemistry, including Jacques, Collet and Wilen: Enantiomers, Racemates and Resolutions, 1981, and Eliel, Stereochemistry of Carbon Compounds , 1962.
The skilled chemist would also review a number of well-known chemical journals including Journal of American Chemical Society , Angewante Chemie , Journal of Organic Chemistry, Journal of Medicinal Chemistry, Tetrahedron , Tetrahedron Letters, Journal of the Royal Chemical Society (Chemical Communications, Perkin Series) and Synthesis . [ 132 ] One would use Chemical Abstracts to search for patents and journal articles. This was a non-computerized keyword system. [ 133 ] The skilled chemist would reject certain methods such as chiral pool or asymmetric synthesis.
The best way to obtain gram quantities to allow for analysis would be by resolution of diastereomers. The skilled chemist would recognize that the diol possessed functional groups or “handles” which made resolution by formation of a covalent diastereomer obvious and easy to carry out. There would be almost no risk of ring closure failure. [ 134 ] In his opinion, a skilled chemist at the time would have been able to develop a scheme based solely on general knowledge without consulting any literature. However a search would turn up Baldwin’s Rules for Ring Closure , 1976.
These rules would show that when a nucleophile and a leaving group in the same compound are separated by four carbons, a ring closure is favoured under the appropriate conditions. The diol would be so favoured. Atoms can be linked by single, double or triple bonds. If all atoms in a compound are linked by single bonds, the compound is said to be fully saturated. If certain atoms are double or triple bonded, the compound is said to be unsaturated. Although the diagrams in the Baldwin paper do not show unsaturated systems, the skilled chemist - but as it turns out not Dr.
Davies - would not conclude that the rules apply only to completely saturated systems. [ 135 ] There would be an S N 2 reaction. He said at paragraph 172 of his report: “Selecting an appropriate leaving group and setting up basic conditions for deprotonation reactions are part of the routine work of the skilled chemist and are neither time consuming nor challenging.” He had an opportunity to review Lundbeck’s laboratory notes and noted Mosher’s acid chloride being used to form a covalent diastereomeric ester of the Citalopram diol.
He did not think this particularly unusual as there is a reference thereto in one of the leading specialist texts: Enantiomers, Racemates and Resolutions , 1981, by Jacques, Collet and Wilen. [ 136 ] Dr. Dannheiser was also of the view that chemical resolution would be the preferred method to use to arrive at the enantiomers of Citalopram. In so doing, he rejected other possibilities such as asymmetric synthesis, chiral pool and kinetic resolution. [ 137 ] In 1988, the skilled addressee would form covalent diastereomers of the diol precursor and then separate them from each other using chromatography.
The separated diastereomers could then be readily converted into the enantiomers of Citalopram. In his view, this was straightforward chemistry. Although a separation process could be carried out by crystallization, chromatography would be more suitable at it would exploit differences between compounds to a greater extent. [ 138 ] Chemical resolution would be the preferred method because a look at Citalopram shows that the compound has one stereogenic centre. There is a six membered-aromatic ring with a fluorine and a three-carbon chain ending in a dimethylamino group.
One would recognize that the compound contains the following functional groups:
i. a nitrate nitrile ( i.e. cyano) group; ii. a tertiary amine group; iii. two aromatic rings; iv. a five-membered cyclic ether. One would recognize that the compound contains a phthalan or dihydroisobenzofuran core. [ 139 ] The skilled addressee would have a strong expectation of success by forming covalent diastereomers of the 1,4-diol precursor using ordinary chromatography to separate those diastereomers and then to convert them into the enantiomers of Citalopram.
The diol would be chosen because it features a primary hydroxyl group for preparing covalent diastereomers and in the main group for the formation of salts. The central challenge would be the construction of the five-membered cyclic ether with a quaternary (fully substituted) carbon attached to the oxygen atom. [ 140 ] The most common method for the synthesis of such ethers involved a reaction called a “nucleophilic substitution” with an alcohol functioning as the nucleophilic partner. This reaction is one in which the nucleophile replaces a leaving group.
The leaving group is an atom or a group of atoms that is able to accept the electron density of the bond that breaks during a substitution or elimination reaction. Under basic conditions the skilled chemist would know it would be necessary to convert one hydroxyl group into a leaving group in order to achieve cyclization. [ 141 ] Once diastereomeric esters were separated, one would cleave the ester to provide the enantiomers of the diol. This would not compromise the stereogenic centre and, therefore, no racemisation would take place.
There are various ways and means by which this could be done, including saponification with an aqueous base or reduction using a reducing agent. [ 142 ] The chemist could choose from a variety of chiral acids described in the literature and discussed in Jacques et al ’s book. This would include tartaric acid. The chemist would choose solvents such as alcohols and focus on chiral acid and solvent combinations that resulted in crystalline salts with the amine and would vary concentrations, temperature and amounts. [ 143 ] Dr. Davies had a different point of view.
He agreed that diastereomers have more or less pronounced differences in their physical properties and may possibly be separated by distillation, crystallization or chromatography. [ 144 ] He described Citalopram as follows: the core of the molecule is a dihydroisobenzofuran core (also called a phthalan structure). Attached to this core is the –C≡N group which is referred to as a nitrile or cyano, depending on context. There is also an aromatic ring (benzene) with a fluorine atom, and finally a three-carbon chain which ends with a tertiary amine.
This means that the nitrogen atom is linked to three carbon atoms with no hydrogen atom. He then discussed five-membered cyclic ethers and conformation. Electron pairs repel each other so the favourite shape of more complicated molecules is one which seeks to minimize the interaction of electron pairs on adjacent atoms as well as around all the individual atoms. [ 145 ] He then discussed nucleophiles and electrophiles. Nucleophiles are electron rich and characterized by a lone pair of electrons, for instance water (H 2
O) and ammonia (NH 3 ). Electrophiles are electron poor and are prepared to form a new covalent bond using a pair of electrons provided to them by another atom or molecule. They carry either a positive or a partial positive charge. A new bond can be formed when a nucleophilic reagent approaches an electrophilic reagent. As an example, when ammonia reacts with hydrogen chloride (HCL), both gases, ammonium chloride is produced, a solid salt. [ 146 ] He went on to discuss nucleophilic substitution reactions.
When a nucleophile reacts with a carbon atom there is a partial positive charge due to being bonded to a more electronegative atom or group of atoms. The result is the electronegative atom is lost as a leaving group as it is substituted by the nucleophile. There are two main mechanisms known as S N 1 and S N 2, both of which can be used in ring closure reactions. S N 1 is a two-step process. In the first step, a group, the leaving group, is lost to give a positively charged intermediate. In the second step, the nucleophile attacks the intermediate from either side to give the product.
This reaction is not stereospecific, so that even if a single enantiomer of the starting material is used, substitution by this S N 1 process will generally result in a racemate. [ 147 ] S N 2 substitution is a single-step process. The nucleophile must attack the central carbon atom at a 180 degree angle from the
leaving group at the same time as the leaving group departs. When a single enantiomer of the starting material is used, an S N 2 process results in a single enantiomer of the product. If a single enantiomer of a chiral nucleophile is employed in the substitution reaction with a non-chiral starting material, the process will result in a single enantiomer of the product, regardless of whether the reaction occurs through a S N 1 or S N 2 pathway.
When an S N 2 reaction occurs, the molecular shape and orientation are important as the various reactive parts need to line up correctly. [ 148 ] In his view, the difference between saturated and non-saturated systems is most important. A saturated system is one that contains no carbon-carbon double bonds. An unsaturated system contains a carbon-carbon double bond; the two ends cannot approach so easily due to the rigid shape surrounding the double bond. [ 149 ] The Citalopram molecule is a base because it comprises an amino group.
This free base can thus make a salt with an acid. [ 150 ] In his view, a literature search in 1988 would not have been as routine as suggested by Drs. Semmelhack and Dannheiser, neither of whom actually performed a search as if it were 1988. While today one might use an internet search engine such SciFinder, at the time one would be using hard copies of the Chemical Abstract . With respect to Citalopram, one would have looked for patents and used keywords such as “Citalopram”, “Phthalan” and “Isobenzofuran”. Broader terms would have turned up far too many documents, most of which would be irrelevant.
The skilled person would also look for specific resolution methods, using keywords such as “enantiomers”, “diastereomers”, “resolving agents” and “chiral HPLC”. These searches would have been time consuming and would have to be found within a library or ordered from other libraries. A thorough search would require several trips to a library and often would take a few weeks. [ 151 ] As to common general knowledge, he opined that one would resort to a leading textbook, the 5 th Edition of Morrison and Boyd’s Organic Chemistry .
He also referred to three specialized books which he did not think the person skilled in the art would have had readily at hand. One was the book by Jacques, Collet and Wilen, which he considered very advanced. He was surprised that Dr. Bøgesø had recourse to it. [ 152 ] He was of the view that resolution was a black art and was a special kind of job that required a special kind of approach, as indeed noted by Morrison and Boyd. [ 153 ] The difference between the innovative concept and the state of the art is that the ‘452 patent is for a new substance useful as an anti-depressant.
The prior art did not disclose or enable the manufacture of this enantiomer of Citalopram. It had never been made before. Its properties had never been established; they were unknown and unexpected. The process it disclosed is novel and inventive. [ 154 ] Unlike Drs. Semmelhack and Dannheiser, he was of the view that the skilled person would have first attempted to resolve Citalopram, rather than a precursor or derivative thereof, of which there were more than one.
However, as above said, I think someone interested in obtaining the enantiomers of Citalopram would have used one compound and if that failed, would use another. However, it is quite true that using the diol involves an additional chemical step. Converting the diol to Citalopram required ring closure to form a five-membered oxygen containing a Phthlan ring which puts in issue the S N 1 and S N 2 mechanisms and the fixed 180 degrees chemistry. There are distinctions between saturated and non-saturated systems which led him to the Baldwin Rules. [ 155 ] In commenting on Dr.
Dannheiser’s report, he said that the Baldwin Rules analysis had been based on saturated systems and did not take into account disfavoured stereoelectronics of the transition state in unsaturated systems such as Citalopram. In his opinion, the Rules might form the basis of quibbling among academics but would not have provided any guidance to the person skilled in the art in 1988. In his opinion, the Baldwin Rules only related to saturated systems and a skilled reader would not consider them because the closure of the intermediate diol occurred in a non-saturated system, of which Citalopram is one.
The Citalopram diol had an unsaturated double bond in the linking chain and so did not fall within the “favoured” molecules specified by Dr. Baldwin. [ 156 ] This led Apotex to call Sir Jack Baldwin in reply. Lundbeck first attempted to have his report struck on the grounds that Apotex was “sand-bagging” I do not think that was the case. In any event, a compromise was reached in that I gave Lundbeck leave to recall Dr. Davies in sur-reply, which it did not. [ 157 ] Dr.
Baldwin testified that although the examples in his rules were of saturated systems, the skilled person would know they applied to unsaturated systems as well. In the 25 years they worked together, Dr. Davies never expressed the opinion he has in this case. More to the point, however, is that in those 25 years the two of them never once discussed the Baldwin Rules! I find that while Dons
might, or might not, discuss the Rules over a cup of tea, they would not have come to the mind of the ordinary chemist and led him or her to conclude that something was obvious to try. [ 158 ] Indeed, to make his point that his rules would apply to both saturated and unsaturated systems, Dr. Baldwin referred to an
article in 1989 about Japanese beer hops. I do not care how widely read the “ordinary” medicinal chemist working in a pharmaceutical lab post-1988 was. Although post-art may simply confirm the obvious, I simply cannot accept that he or she would have come across that
article and be inspired, although unimaginatively, to carry out one chemical reaction rather than another. [ 159 ] Another example of the experts debating at a level far beyond the unimaginative skilled addressee of the patent who, of course, had not read it, is the “contretemps” between Dr. Dannheiser and Dr. Davies. Dr. Dannheiser, unlike Dr. Davies, was of the opinion that the ordinary chemist in 1988 would have regarded an S N 2 type ring closure to be a reasonable step in the synthesis of an enantiomer of Citalopram. [ 160 ] On the other hand, Dr.
Davies thought that such a chemist would have knowledge of stereochemical principles and would have performed a conformational analysis which would have led him or her
[…]
Loading document…